In a recent interview, Andrea Pezzella, MD, URPS, FACOG, of Southern Urogynecology Wellness & Aesthetics in West Columbia, South Carolina, shared insights on Neuspera’s innovative integrated sacral ...

Key Takeaways The Co-PSMA trial compares 64Cu-SAR-bisPSMA and 68Ga-PSMA-11 PET/CT for detecting prostate cancer recurrence post-radical prostatectomy. 64Cu-SAR-bisPSMA has received FDA fast track ...

Data showed that African American men faced significant delays in treatment initiation. A recent analysis demonstrated that although African American men and non-African American men had comparable ...

On Saturday, August 2, 2025, Northwestern University is hosting a course titled "Advances in Genitourinary Robotic Reconstruction." In this video, Ziho Lee, MD, the course director and assistant ...

BCAN's $1 million Continuity Grant supports bladder cancer research projects impacted by federal funding terminations, ensuring continued progress in the field. Eligible projects include basic, ...

In this landmark episode of Pearls & Perspectives, host Amy Pearlman, MD, sits down with one of the world’s foremost experts in sexual medicine, John P. Mulhall, MD, of Memorial Sloan Kettering Cancer ...

A panelist discusses how different abiraterone formulations require specific steroid combinations—prednisone with traditional abiraterone and prednisolone with microformulation—and the importance of ...

Mina M. Fam, MD, discusses some of the common misconceptions that patients have when seeking testosterone replacement therapy.

Howard B. Goldman, MD, FACS, discusses innovations such as tibial nerve stimulation devices, pudendal nerve targeting, and alternative stimulation frequencies.

Data from the #HOPE4KIDNEY trial is intended to support submission for regulatory clearance of the Edison Histotripsy System.

Nivolumab plus ipilimumab improved overall survival and response rates over sunitinib in advanced renal cell carcinoma, with a median follow-up of 9.3 years. The combination showed sustained benefits ...

Key Takeaways Sasanlimab combined with BCG improved event-free survival in high-risk NMIBC patients, particularly those with CIS and T1 tumors. Subgroup analyses showed EFS benefits across different ...